This Week’s CGT News: Base Editing Takes Aim at Cholesterol

Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M

• June 1, 2026

• 5 min

• The Medicine Maker